Shanghai Pharmaceuticals Holding Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Shanghai Pharmaceuticals Holding Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Shanghai Pharmaceuticals Holding Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Shanghai Pharmaceuticals Holding Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Shanghai Pharmaceuticals Holding Co Ltd (Shanghai Pharma) manufactures, markets, and distributes healthcare products. Shanghai Pharma's major products include innovative drugs, chemical drugs, traditional Chinese medicines, and treatments for rare diseases. These products are primarily used in the cardiovascular system, digestive tract and metabolism, systemic anti-infection, central nervous system, anti-tumor, and immunomodulatory systems, and the musculoskeletal and respiratory systems. It also provides retail, distribution, and supply chain solutions to pharmaceutical manufacturers and dispensers, and operates retail and chain pharmacies. The company serves medical institutions, retail institutions, and partners at various levels. Shanghai Pharma operates a direct sales network covering provinces, municipalities, and autonomous regions in China, and distributes its products both domestically and internationally. Shanghai Pharma is headquartered in Shanghai, China.
Headquarters
China
Address
Shanghai Pharmaceutical Mansion, No.200 Taicang Road, 200020
Website
www.sphchina.com
Telephone
86 216 3730908
No of Employees
49,608
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
601607 (SHA)
Revenue (2024)
$39.5B
3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
25.7%
(2024 vs 2023)
Market Cap*
$8.0B
Net Profit Margin (2024)
XYZ
22.4%
(2024 vs 2023)
* As of and is in US$
Shanghai Pharmaceuticals Holding Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Pharmaceutical Products | Retail Services | Sine |
| Traditional Chinese Medicine | Distribution Services | Lei’s |
| Chemical Drugs | Production Services | Dragon & Tiger |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In April, the company signed a memorandum of understanding with Shanghai Center for Drug Evaluation and Inspection (CDE) on collaborative innovation and integrated services, and carried out the first integrated service with traditional Chinese medicine as the theme. |
| 2026 | Contracts/Agreements | In March, the company entered into an agreement with Henlius Biotech to focus on expanding and deepening hospital market development and international business. |
| 2026 | Regulatory Approval | In March, the company's subsidiary Shanghai Hefeng Pharmaceutical Co Ltd received approval for dihydroxypropyltheophylline injection from the National Medical Products Administration. |
Competitor Comparison
| Key Parameters | Shanghai Pharmaceuticals Holding Co Ltd | China National Accord Medicines Corporation Ltd | Nanjing Pharmaceutical Group Co Ltd | Tasly Pharmaceutical Group Co Ltd | Simcere Pharmaceutical Group Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shanghai | Shenzhen | Nanjing | Tianjin | Nanjing |
| State/Province | Shanghai | Guangdong | Jiangsu | Tianjin | Jiangsu |
| No. of Employees | 49,608 | 28,336 | 4,697 | 10,563 | 7,038 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Yang Qiuhua | Chairman | Executive Board | 2024 | 54 |
| Li Yongzhong | Chief Executive Officer; Director; Vice President | Executive Board | 2019 | 56 |
| Shen Bo | Director; President | Executive Board | 2019 | 53 |
| Zhou Yadong | Chief Financial Officer; Vice President | Senior Management | 2025 | 54 |
| Dong Ming | Director | Executive Board | 2023 | 50 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer